[go: up one dir, main page]

IL196643A0 - Methods and tools for the therapy of neurodegenerative pathologies - Google Patents

Methods and tools for the therapy of neurodegenerative pathologies

Info

Publication number
IL196643A0
IL196643A0 IL196643A IL19664309A IL196643A0 IL 196643 A0 IL196643 A0 IL 196643A0 IL 196643 A IL196643 A IL 196643A IL 19664309 A IL19664309 A IL 19664309A IL 196643 A0 IL196643 A0 IL 196643A0
Authority
IL
Israel
Prior art keywords
therapy
tools
methods
neurodegenerative pathologies
pathologies
Prior art date
Application number
IL196643A
Original Assignee
Exonhit Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exonhit Therapeutics Sa filed Critical Exonhit Therapeutics Sa
Publication of IL196643A0 publication Critical patent/IL196643A0/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406Neurotransmitters
    • G01N33/9426GABA, i.e. gamma-amino-butyrate
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL196643A 2006-07-21 2009-01-21 Methods and tools for the therapy of neurodegenerative pathologies IL196643A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0606698A FR2904113A1 (en) 2006-07-21 2006-07-21 METHODS AND TOOLS FOR THERAPY OF NEURODEGENERATIVE PATHOLOGIES
PCT/FR2007/051706 WO2008009868A2 (en) 2006-07-21 2007-07-20 Methods and tools for the therapy of neurodegenerative pathologies

Publications (1)

Publication Number Publication Date
IL196643A0 true IL196643A0 (en) 2009-11-18

Family

ID=37736076

Family Applications (1)

Application Number Title Priority Date Filing Date
IL196643A IL196643A0 (en) 2006-07-21 2009-01-21 Methods and tools for the therapy of neurodegenerative pathologies

Country Status (11)

Country Link
US (1) US20090317842A1 (en)
EP (1) EP2047277A2 (en)
JP (1) JP2009544964A (en)
KR (1) KR20090086386A (en)
CN (1) CN101542289A (en)
AU (1) AU2007274872A1 (en)
CA (1) CA2658464A1 (en)
FR (1) FR2904113A1 (en)
IL (1) IL196643A0 (en)
WO (1) WO2008009868A2 (en)
ZA (1) ZA200901094B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010046332A1 (en) * 2008-10-20 2010-04-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for detecting soluble amyloid precursor protein (app) alpha and/or soluble app beta
WO2018015296A1 (en) * 2016-07-20 2018-01-25 Vib Vzw Therapeutic agents for neurological and psychiatric disorders
JP6405549B2 (en) * 2016-12-22 2018-10-17 国立研究開発法人理化学研究所 Acute coronary syndrome marker and its use
EP3628315A1 (en) 2018-09-28 2020-04-01 Université de Caen Normandie Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases
EP3628660A1 (en) 2018-09-28 2020-04-01 Université de Caen Normandie Donecopride and flucopride as neuroprotective agents in the treatment of neurodegenerative diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8702338A (en) * 1987-09-30 1989-04-17 Mathilde Elisabeth Boon En Lan METHOD FOR PROCESSING OF (BIO-) CHEMICAL OR (MICRO-) BIOLOGICAL REACTIONS USING MICRO-WAVES, METHODS AND APPARATUS THEREFOR
US5843794A (en) * 1992-03-26 1998-12-01 Montefiore Medical Center Technique for the prevention of false positive reactions in immunological testing due to C1 and C1q components of the complement and method for screening for rheumatic factor
GB0012671D0 (en) * 2000-05-24 2000-07-19 Merck Sharp & Dohme Therapeutic agents
DE50103881D1 (en) * 2001-06-12 2004-11-04 Wiltfang Jens Monoclonal antibody, mbAb 1E8, which is specific for the first two N-terminal amino acids of amyloid beta peptides and its use for the detection of amyloid beta peptides and / or sAPPa
GB0207249D0 (en) * 2002-03-27 2002-05-08 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
WO2008009868A3 (en) 2008-05-08
US20090317842A1 (en) 2009-12-24
KR20090086386A (en) 2009-08-12
AU2007274872A1 (en) 2008-01-24
CA2658464A1 (en) 2008-01-24
FR2904113A1 (en) 2008-01-25
EP2047277A2 (en) 2009-04-15
CN101542289A (en) 2009-09-23
WO2008009868A2 (en) 2008-01-24
ZA200901094B (en) 2010-01-27
JP2009544964A (en) 2009-12-17

Similar Documents

Publication Publication Date Title
IL196559A0 (en) Combination therapy
GB0614947D0 (en) Epitope reduction therapy
GB0718972D0 (en) Compounds and methods of making the compounds
GB0609492D0 (en) Therapeutic agents
HUE054365T2 (en) Boronophthalides for therapeutic use
GB0608928D0 (en) Therapeutic agents
GB0601962D0 (en) Therapeutic agents
IL196556A0 (en) Combination therapy
EP2054061A4 (en) Combination therapy
ZA200807884B (en) Milling apparatus
GB0616214D0 (en) Therapeutic Agents
PL2601972T3 (en) Non-lithotripsic kidney-stone therapy
ZA200902203B (en) Combination therapy
ZA200901094B (en) Methods and tools for the therapy of neurodegenerative pathologies
GB0611152D0 (en) Therapeutic agents
GB0607946D0 (en) Mono and combination therapy
GB0620818D0 (en) Therapeutic agents
GB0607949D0 (en) Mono and combination therapy
IL226363A0 (en) Compounds and methods for the treatment of cancer
GB0620059D0 (en) Therapeutic agents
GB0609676D0 (en) Therapeutic agents
ZA200807678B (en) Meridamycin analogues for the treatment of neurodegenerative disorders
HK1131205A (en) Methods and tools for the therapy of neurodegenerative pathologies
GB0607153D0 (en) Therapeutic Method
GB0622195D0 (en) Therapeutic agents